Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy and tolerability of budesonide aqueous nasal spray treatment in patients with nasal polyps
Autore:
Jankowski, R; Schrewelius, C; Bonfils, P; Saban, Y; Gilain, L; Prades, JM; Strunski, V;
Indirizzi:
Hop Cent, Dept Otorhinolaryngol, Nancy, France Hop Cent Nancy FranceHop Cent, Dept Otorhinolaryngol, Nancy, France Hop Boucicaut, Dept Otorhinolaryngol, Paris, France Hop Boucicaut Paris France cicaut, Dept Otorhinolaryngol, Paris, France CHU Clermont Ferrand, Clermont Ferrand, France CHU Clermont Ferrand Clermont Ferrand France , Clermont Ferrand, France Hop Bellevue, Dept Otorhinolaryngol, St Etienne, France Hop Bellevue St Etienne France ept Otorhinolaryngol, St Etienne, France Ctr Hosp Nord Amiens, Dept Otolaryngol, Amiens, France Ctr Hosp Nord Amiens Amiens France ns, Dept Otolaryngol, Amiens, France AstraZeneca Res & Dev, Clin Operat, Lund, Sweden AstraZeneca Res & Dev Lund Sweden Res & Dev, Clin Operat, Lund, Sweden
Titolo Testata:
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
fascicolo: 4, volume: 127, anno: 2001,
pagine: 447 - 452
SICI:
0886-4470(200104)127:4<447:EATOBA>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
POWDER; MANAGEMENT; PATENCY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Jankowski, R H Poincare Univ, Cent Hosp, Dept Otorhinolaryngol Head & NeckSurg, F-54000 Nancy, France H Poincare Univ Nancy France F-54000 F-54000 Nancy, France
Citazione:
R. Jankowski et al., "Efficacy and tolerability of budesonide aqueous nasal spray treatment in patients with nasal polyps", ARCH OTOLAR, 127(4), 2001, pp. 447-452

Abstract

Objective: To assess the efficacy and tolerability of once-daily treatmentwith budesonide aqueous nasal spray in patients with nasal polyps. Design: Randomized, double-blind, placebo-controlled, parallel-group study. Setting: Sixteen hospital clinics. Patients: One hundred eighty-three patients with moderate-sized nasal polyps causing clinically significant symptoms during a 1-week run-in period. Interventions: Patients were randomized to receive 1 of the following 4 budesonide aqueous nasal spray treatments: 128 mug once daily in the morning and placebo in the evening, 128 mug twice daily, 256 mug once daily in the morning and placebo in the evening, or placebo for 8 weeks. Nasal polyp size was scored and peak nasal inspiratory flow was measured at clinic visits at the beginning and end of the run-in period and after 4 and 8 weeks' treatment. Patients recorded daily peak nasal inspiratory flow, symptom scores tie, blocked nose, runny nose, and sneezing) and sense of smell on diary cards. Main Outcome Measures: Mean change in nasal polyp size at the end of treatment; mean changes in combined and individual symptom scores. Results: All doses of budesonide aqueous nasal spray significantly (P<.01)reduced polyp size; no significant differences were noted between the 4 treatment groups. The mean improvement in clinic peak nasal inspiratory flow at 8 weeks was 65.9 L/min with budesonide aqueous nasal spray, 128 <mu>g twice daily; 71.6 L/min with budesonide aqueous nasal spray, 256 mug once daily; and 54.6 L/min with budesonide aqueous nasal spray, 128 mug once daily tall P<.001 vs placebo). Combined and individual symptom scores and sense of smell improved significantly in all budesonide-treated groups; the effecton symptoms became apparent within 1 to 2 days of the first dose. Budesonide aqueous nasal spray was well tolerated. Conclusions: Doses of budesonide aqueous nasal spray, 128 <mu>g once daily, were found to be effective in the treatment of nasal polyps, and doses ofbudesonide aqueous nasal spray, 256 mug once daily, did not show any significant additional efficacy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 10:50:33